TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Ondansetron Administration to Children With Gastroenteritis, Vomiting and SOME Dehydration in EDs in Pakistan

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 6 - 59 months (0.5 - 5 years)~* Symptoms consistent with gastroenteritis (must have a \& b)~  1. 1 episode of nonbilious, nonbloody vomiting within the 4 hours preceding triage The requirement for only 1 vomiting episode is based on prior work which similarly required 1 vomiting episode within 4 hours of triage. The later study reported a 17% absolute reduction in the use of IV rehydration. The vast majority of children seeking care and enrolled in the aforementioned study had a significantly greater number of vomiting episodes in the preceding 24 hour (mean \>9 episodes).29~ 2. Presence of ≥ 1 episode of diarrhea during the illness We require the presence of only 1 diarrheal stool to enhance our probability of enrolling children with enteritis (as opposed to other diagnoses).~In fact, of the 8 RCTs performed using antiemetics in children with gastroenteritis in developed countries, only 1 even required the presence of any diarrhea as part of the eligibility criteria (and that study required a single diarrheal stool).~- Presence of SOME dehydration - 2 or more of the following signs: i. Restlessness, irritability; ii. Sunken Eyes; iii.Drinks eagerly, thirsty; iv.Skin pinch goes back slowly~Exclusion Criteria:~* Weight \<8 kg~* Vomiting or diarrhea for \> 7 days~* Malnutrition: The WHO definition will be employed - weight for height below -3z scores of the median WHO growth standards~* Severe dehydration (WHO criteria) or hypotension defined as a systolic blood pressure \<70 mm Hg in infants 1 month to 12 months, \< 70 mm Hg + (2 x age in years) in children 1-10 years, \< 90 mm Hg in children ≥ 10 years~* Prior abdominal surgery (excluding hernia)~* Bilious or bloody vomitus~* Known hypersensitivity to ondansetron or any serotonin receptor antagonist~* History or family history of prolonged QT syndrome~* Taking apomorphine or any medication that is generally accepted as having a risk of causing torsades de pointes~* Patients previously enrolled in the study~* Follow-up will not be possible

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 59 Months
- Healthy Volunteers: f

Study Arms:
- Ondansetron (Type: EXPERIMENTAL): 4 mg oral disintegrating tablet of ondansetron~Participant weight 8-15 kg = half dose (2mg) Participant weight greater than 15 kg = full dose (4mg)
- Placebo (sugar pill) (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With Acromegaly

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female patients, ≥18 years at screening~* Able to provide written informed consent to participate in the trial prior to any trial related procedures are performed~* Diagnosis of acromegaly by historical evidence of (persistent or recurrent) acromegaly~* Treatment with a stable dose of octreotide LAR or lanreotide ATG for at least 3 months as monotherapy prior to screening~* IGF-1 levels ≤1xULN at screening~* Adequate liver, pancreatic, renal and bone marrow functions~* Normal ECG~Exclusion Criteria:~* GH ≥2.5 μg/L at screening (cycle)~* Have received medical treatment for acromegaly with pasireotide (within 6 months prior to screening), pegvisomant (within 3 months prior to screening), dopamine agonists (within 3 months prior to screening) or other investigational agents (within 30 days or 5 half-lives prior to screening \[whichever is longer\]~* Patients who usually take octreotide LAR or lanreotide ATG less frequently than every 4 weeks (e.g. every 6 weeks or 8 weeks)~* Patients with compression of the optic chiasm causing any visual field defect for whom surgical intervention is indicated~* Patients who have undergone major surgery/surgical therapy for any cause within 1 month from screening~* Patients who have undergone pituitary surgery within 6 months prior to screening~* Patients who have received prior pituitary irradiation~* Patients with poorly controlled diabetes mellitus (hemoglobin A1c \>8.0%)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CAM2029 (octreotide subcutaneous depot) (Type: EXPERIMENTAL): CAM2029 (octreotide subcutaneous depot) 20mg/1.0 mL for 20 mg dose, subcutaneous injection once monthly, six months treatment. If down-titration is required, 10mg/0.5 mL for 10 mg dose is available.
- Matching placebo (Type: PLACEBO_COMPARATOR): Placebo (subcutaneous depot) 1.0 mL, subcutaneous injection once monthly, six months treatment. If down-titration is required, 0.5 mL dose is available.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Combination Chemotherapy for the Treatment of Indian Kala-Azar

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Clinical diagnosis of active VL with consistent signs and symptoms (e.g., fever, splenomegaly).~* Confirmed diagnosis by bone-marrow or splenic aspirate smear showing characteristic amastigotes.~* Male or female.~* Ages 12 to 65 years.~* Both newly diagnosed cases and patients who have received previous treatment (in the latter case a 2-week wash-out will be required before starting the study treatment).~* WBC \> 1,000/mm3.~* Hemoglobin ≥ 4 g/dL~Exclusion Criteria:~* Pregnancy or breast-feeding.~* HIV positive serology.~* ASAT, ALAT, AP ≥ 3 times upper limit of normal range.~* Bilirubin ≥ 2 times upper limit of normal range.~* Prothrombin time ≥ 5 seconds above control.~* Serum creatinine or BUN ≥ 1.5 times upper limit of normal range.~* Any medical condition or situation that compromises compliance with study procedures.~* HIV

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 65 Years
- Healthy Volunteers: None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Treatment Uptake Chatbot for Eating Disorders

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 16.0

Eligibility Criteria:
Inclusion Criteria:~* U.S. resident~* English-speaking~* Age 18 years or older~* Owns a personal smartphone~* Screens positive for a Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) clinical or subclinical eating disorder~* Not currently receiving treatment for an eating disorder~Exclusion Criteria:~* Non-U.S. resident~* Younger than 18 years old~* Does not own a personal smartphone~* Does not screen positive for a DSM-5 clinical or subclinical eating disorder~* Screens positive for Avoidant Restrictive Food Intake Disorder~* Currently receiving treatment for an eating disorder

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Repeated Administration (Type: EXPERIMENTAL): None
- Personalized Recommendation (Type: EXPERIMENTAL): None
- Motivational Interviewing (Type: EXPERIMENTAL): None
- Core Modules Only (Type: EXPERIMENTAL): None
- Motivational Interviewing, Personalized Recommendation, Repeated Administration (Type: EXPERIMENTAL): None
- Motivational Interviewing, Repeated Administration (Type: EXPERIMENTAL): None
- Motivational Interviewing, Personalized Recommendation (Type: EXPERIMENTAL): None
- Personalized Recommendation, Repeated Administration (Type: EXPERIMENTAL): None
- Psychoeducation (Type: EXPERIMENTAL): None
- Psychoeducation, Repeated Administration (Type: EXPERIMENTAL): None
- Psychoeducation, Personalized Recommendation (Type: EXPERIMENTAL): None
- Psychoeducation, Motivational Interviewing (Type: EXPERIMENTAL): None
- Psychoeducation, Motivational Interviewing, Personalized Recommendation (Type: EXPERIMENTAL): None
- Psychoeducation, Personalized Recommendation, Repeated Administration (Type: EXPERIMENTAL): None
- Psychoeducation, Motivational Interviewing, Repeated Administration (Type: EXPERIMENTAL): None
- Psychoeducation, Motivational Interviewing, Personalized Recommendation, Repeated Administration (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Knee Osteoarthritis by Intra-articular Injection of Bone Marrow Mesenchymal Stem Cells

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Males and females between 50 and 80 year old.~* Diagnosis of knee OA according to the criteria of osteoarthritis of the ACR (American College of Rheumatology).~* Joint pain equal or greater than 2.5 points on the visual analogue scale (VAS).~* Radiological Classification: Kellgren-Lawrence scale greater or equal to 2.~* Body mass index between 20 and 35 kg/m2.~* Ability to follow during the study period.~Exclusion Criteria:~* Bilateral Osteoarthritis of the Knee requiring treatment in both knees.~* Previous diagnosis of polyarticular disease.~* Severe mechanical deformation.~* Arthroscopy during the previous 6 months.~* Intraarticular infiltration of hyaluronic acid in the last 6 months.~* Systemic autoimmune rheumatic disease.~* Poorly controlled diabetes mellitus.~* Blood dyscrasias.~* Immunosuppressive or anticoagulant treatments.~* Treatment with corticosteroids in the 3 months prior to inclusion in the study.~* NSAID therapy within 15 days prior to inclusion in the study.~* Patients with a history of allergy to penicillin or streptomycin.~* Allergy to hyaluronic acid or poultry proteins.

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Hialuronic acid (Type: ACTIVE_COMPARATOR): Single intraarticular injection of Hyaluronic acid (Hyal One)
- Hyaluronic acid and MSC 10 (Type: ACTIVE_COMPARATOR): Single intraarticular injection of Hyaluronic acid (Hyal One) 10 million Bone marrow mesenchimal stem cells
- Hyaluronic acid AND MSC 100 (Type: ACTIVE_COMPARATOR): Single intraarticular injection of Hyaluronic acid (Hyal One) 100 million Bone marrow mesenchimal stem cells

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Severity-Adapted Clinical Trial of Diminished Bone Mineral Density in Acute Lymphoblastic Leukemia Survivors

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient is a survivor of acute lymphoblastic leukemia.~* Patient was treated on St. Jude Children's Research Hospital's Total XI, XII, or XIII treatment protocol.~* Patient is at least five years out from completion of therapy and is in first remission~Exclusion Criteria:~* Active disease~* Pregnant or lactating females~* Inability to chew and swallow pills~* Currently taking more than 800 mg supplemental calcium or 800 IU vitamin D~* Anemia

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1A (Type: PLACEBO_COMPARATOR): Nutritional counseling + placebo
- 1B (Type: EXPERIMENTAL): Nutritional counseling + supplementation with calcium, 1000mg/day + vitamin D, 800 units/day, for a 2 year period

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Retapamulin as a Decolonizing Agent for MRSA

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Admission to the general pediatric floor and pediatric intensive care units at NYU Langone Medical Center or visit to study team members at ODA clinic (Park Ave locations) in Williamsburg Brooklyn.~2. Ages 9 months to 17 years~3. Residing in the zip codes which reflect Orthodox Jewish neighborhoods where there is a current outbreak of this strain of MRSA.~4. Nasal and/or rectal culture positive for mupirocin-resistant methicillin-resistant Staphylococcus aureus (MRSA)~Exclusion Criteria:~An individual who meets any of the following criteria will be excluded from participation in this study:~1. Pregnant or lactating~2. Unable to appropriately consent~3. Open sores in either of the study sites (nares or rectum)~4. Recent surgical procedure to either study site (nares or rectum)~5. Concurrent use of Rifampin or Trimethoprim/Sulfamethoxazole~6. Current active MRSA infection~7. Immunocompromised~8. Presence of endotracheal tube, tracheostomy tube or other foreign body in upper airway

- Gender: ALL
- Minimum Age: 9 Months
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Retapamulin (Type: EXPERIMENTAL): Thin layer of ointment applied twice a day for five days. Study drug will be applied to the nares and peri-rectal area twice a day for 5 consecutive days.
- Placebo (Type: PLACEBO_COMPARATOR): The placebo used will be a triple purified pharmaceutical grade white petrolatum

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RDX5791 in Healthy Volunteers

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 9.0

Eligibility Criteria:
Inclusion Criteria:~* BMI between 18 and 29.9 kg/m², inclusive~* Females must be of non-childbearing potential; If of child-bearing potential, must have negative pregnancy test and confirm the use of one of the appropriate means of contraception~* Males must agree to use appropriate methods of barrier contraception or have documented surgical sterilization~Exclusion Criteria:~* Diagnosis or treatment of any clinically symptomatic biochemical or structural abnormality of the GI tract~* Any surgery on the small intestine or colon, excluding appendectomy~* Loose stools (Bristol Stool Form Score of 6 or 7) ≥2 days in the past 7 days~* Hepatic dysfunction (\[ALT\] or \[AST\]) \>1.5 times the upper limit of normal or renal impairment~* Any evidence of or treatment of malignancy, excluding non-melanomatous malignancies of the skin~* Use of diuretic medications, medications that are known to affect stool consistency and/or GI motility~* Use of an investigational agent within 30 days prior to Day -2~* Positive virology, alcohol, or drugs of abuse test during screening~* Use of any prescription medication within 7 days before admission to the CPU~* Have had significant blood loss (\>450 mL) or have donated 1 or more units of blood or plasma within 8 weeks prior to study entry

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- RDX5791 10mg QD (SAD phase) (Type: EXPERIMENTAL): 10mg of RDX5791 administered once daily PO fasting
- RDX5791 50mg QD (SAD phase) (Type: EXPERIMENTAL): 50mg of RDX5791 administered once daily PO fasting
- RDX5791 150mg QD (SAD phase) (Type: EXPERIMENTAL): 150mg of RDX5791 administered once daily PO fasting
- RDX5791 450mg QD (SAD phase) (Type: EXPERIMENTAL): 450mg of RDX5791 administered once daily PO fasting
- RDX5791 900mg QD (SAD phase) (Type: EXPERIMENTAL): 900mg of RDX5791 administered once daily PO fasting
- RDX5791 3mg QD (MAD phase) (Type: EXPERIMENTAL): 3mg of RDX5791 administered once daily PO fasting
- RDX5791 10mg QD (MAD phase) (Type: EXPERIMENTAL): 10mg of RDX5791 administered once daily PO fasting
- RDX5791 30 mg QD (MAD phase) (Type: EXPERIMENTAL): 30mg of RDX5791 administered once daily PO fasting
- RDX5791 100 mg QD (MAD phase) (Type: EXPERIMENTAL): 100mg of RDX5791 administered once daily PO fasting

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Oral Phloroglucin (Flospan®) as Premedication of Non-sedative Diagnostic Esophagogastroduodenoscopy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* patients who perform non-sedative endoscopy for diagnosis or screening purposes.~* patients who understand and follow the directions and questionnaires of clinical trials.~* patients who have decided to voluntarily participate in this clinical trial and have agreed in writing~Exclusion Criteria:~* Patients who performed Upper GI surgery.~* Severe gastric outlet obstruction or malformations or gastroparesis~* Patients who have severe cognitive impairment~* Pregnant or lactation patients~* Patients who need to hemostasis for upper GI bleeding~* Hemodynamic unstable patients~* Above American Society of Anesthesiology classification class 4

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: t

Study Arms:
- Phloroglucin group (Type: EXPERIMENTAL): patients taken Phloroglucin(Flospan®)
- Normal saline placebo group (Type: PLACEBO_COMPARATOR): patients taken normal saline placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Venlafaxine and Fluoxetine in the Treatment of Postmenopausal Women With Major Depression

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Female, aged 50 or older, memopausal.~* Meet DSM-IV criteria for current unipolar major depressive disorder.~* The total score of the HAMD-24 is at least 20 at screening and baseline.~* The current depressive episode within 1 year.~* If recurrent depression, the remission of previous episode is at least 5 years from the current episode.~* Providing informed consent form to participate in the study by patients or their legal representatives.~Exclusion Criteria:~* Current Axis I primary psychiatric diagnosis other than major depressive disorder.~* Substance abuse or dependence.~* Patients were also excluded if they had any medical condition that would contraindicate the use of venlafaxine or fluoxetine.~* Organic mental disease, including mental retardation.~* History of clinically significant disease, including any cardiovascular, hepatic, renal, respiratory, hematologic, endocrinologic, or neurologic disease, or clinically significant laboratory abnormality that is not stabilized or is anticipated to require treatment during the study.~* Use of psychiatric agents within 5 days prior to randomization.~* Have proved no response to venlafaxin or fluoxetine by previous treatment.~* Participation in another clinical study within 4 weeks (or longer time according to the local requirement)~* Has received ECT or MECT within 3 months prior to randomization.~* Significant risk of suicidal and/or self-harm behaviors.

- Gender: FEMALE
- Minimum Age: 50 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- venlafaxine (Type: ACTIVE_COMPARATOR): venlafaxine 75-225mg qd
- fluoxetine (Type: ACTIVE_COMPARATOR): fluoxetine 20-60mg qd

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Vincristine, DOXIL (Doxorubicin HCl Liposome Injection) and Dexamethasone vs. Vincristine, Doxorubicin, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Untreated multiple myeloma requiring treatment~* Total cumulative dose of prior doxorubicin can not exceed 240 mg/m2~* Must have measurable disease~* Left Ventricular Ejection Fraction (LVEF) \>= 50 % determined by Multiple Gated Acquisition Scan (MUGA)~* Karnofsky performance status of \>= 60%~* Adequate bone marrow, liver and renal function~* Disease-free from prior malignancies \>= 5 years with the exception of basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the cervix~* Female participants (if of child bearing potential and sexually active) and male participants (if sexually active with a partner of child-bearing potential) must use medically acceptable methods of birth control.~Exclusion Criteria:~* Life expectancy of \>= 3 months~* Pregnant or breast feeding~* History of cardiac disease, with New York Heart Association Class II or greater, with congestive heart failure~* or unstable angina, uncontrolled hypertension or cardiac arrythmias or myocardial infarction within the last 6 months~* Uncontrolled diabetes mellitus or systemic infection~* Nonsecretory myeloma, Monoclonal Gammopathy of Unknown Significance (MGUS) or smoldering myeloma~* Confusion, disorientation, or history of psychiatric illness which may impair patient's ability to give informed consent~* Prior chemotherapy to treat Multiple Myeloma~* Prior radiotherapy to an area greater than 1/3 of the skeleton~* Prior local radiotherapy within 1 week of treatment~* Any investigational agent within 30 days of the first dose of treatment~* Prior single agent dexamethasone (or another corticosteroid) to treat Multiple Myeloma.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete